In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system

Journal of Controlled Release : Official Journal of the Controlled Release Society
Roselena SchuhGuilherme Baldo

Abstract

Mucopolysaccharidosis type I (MPS I) is a multisystemic disorder caused by the deficiency of alpha-L-iduronidase (IDUA) that leads to intracellular accumulation of glycosaminoglycans (GAG). In the present study we aimed to use cationic liposomes carrying the CRISPR/Cas9 plasmid and a donor vector for in vitro and in vivo MPS I gene editing, and compare to treatment with naked plasmids. The liposomal formulation was prepared by microfluidization. Complexes were obtained by the addition of DNA at +4/-1 charge ratio. The overall results showed complexes of about 110 nm, with positive zeta potential of +30 mV. The incubation of the complexes with fibroblasts from MPS I patients led to a significant increase in IDUA activity and reduction of lysosomal abnormalities. Hydrodynamic injection of the liposomal complex in newborn MPS I mice led to a significant increase in serum IDUA levels for up to six months. The biodistribution of complexes after hydrodynamic injection was markedly detected in the lungs and heart, corroborating the results of increased IDUA activity and decreased GAG storage especially in these tissues, while the group that received the naked plasmids presented increased enzyme activity especially in the liver. Furthe...Continue Reading

Citations

Aug 28, 2019·Proceedings of the National Academy of Sciences of the United States of America·Peng GuoMarsha A Moses
Aug 25, 2020·The CRISPR Journal·Lavina Sierra TayPrashant Mali
Oct 1, 2020·PloS One·Michael PöhlerVanessa Sandfort
Jul 28, 2019·Human Gene Therapy·Nerea ZabaletaGloria Gonzalez-Aseguinolaza
Jun 13, 2020·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Andrés Felipe LealCarlos Javier Alméciga-Díaz
Jun 13, 2020·Orphanet Journal of Rare Diseases·Marwa AbdelhakimRobert Hoehndorf
May 1, 2020·Frontiers in Molecular Biosciences·Jacob M FavretDaesung Shin
Jan 17, 2020·International Journal of Molecular Sciences·Edina PolettoNatalia Gomez-Ospina
Jul 1, 2020·Advanced Drug Delivery Reviews·Nina FilipczakVladimir P Torchilin
Feb 13, 2021·Pharmaceuticals·Abdelfattah Faouzi, Valérie Gaëlle Roullin
Aug 11, 2020·Molecular Therapy. Methods & Clinical Development·Martijn P T ErnstW W M Pim Pijnappel
Mar 4, 2021·Expert Opinion on Biological Therapy·Azam SafaryYadollah Omidi
Jul 1, 2021·Journal of Inherited Metabolic Disease·Sarah C HurtDavid T Curiel
Jan 16, 2022·The Journal of Gene Medicine·Luisa Natalia Pimentel VeraHelder F Teixeira

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

© 2022 Meta ULC. All rights reserved